Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anton Camacho

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Vaccines|August 29, 2024
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the CongoEdward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, et al.
Lancet (London, England)|August 8, 2015
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialAna Maria Henao-Restrepo, Ira M Longini, Matthias Egger, et al.
BMJ Public Health|August 4, 2025
Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme ('ENABLE 1.5') - study protocolHenshaw Mandi, Danny Asogun, Olufemi Ayodeji, et al.
Lancet (London, England)|December 27, 2016
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, et al.
Vaccines|August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the CongoHugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
BMC Medicine|November 7, 2024
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)Conall H Watson, Pierre-Stéphane Gsell, Yper Hall, et al.
Plos One|January 14, 2025
Correction: A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocolSuzanne Penfold, Ayola Akim Adegnika, Danny Asogun, et al.
Plos One|March 30, 2023
A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocolSuzanne Penfold, Ayola Akim Adegnika, Danny Asogun, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Vaccines|August 29, 2024
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the CongoEdward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, et al.
Lancet (London, England)|August 8, 2015
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialAna Maria Henao-Restrepo, Ira M Longini, Matthias Egger, et al.
BMJ Public Health|August 4, 2025
Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme ('ENABLE 1.5') - study protocolHenshaw Mandi, Danny Asogun, Olufemi Ayodeji, et al.
Lancet (London, England)|December 27, 2016
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, et al.
Vaccines|August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the CongoHugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
BMC Medicine|November 7, 2024
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)Conall H Watson, Pierre-Stéphane Gsell, Yper Hall, et al.
Plos One|January 14, 2025
Correction: A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocolSuzanne Penfold, Ayola Akim Adegnika, Danny Asogun, et al.
Plos One|March 30, 2023
A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocolSuzanne Penfold, Ayola Akim Adegnika, Danny Asogun, et al.
Pageof 4